FDA Clearance Tracker · P100026-S092
NeuroPace® RNS® System
Last checked: Nov 20, 2026Latest source record: Feb 10, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Feb 10, 2023
Approved
Time to decision
116 days
Received Oct 17, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P100026-S092
- Device name
- NeuroPace® RNS® System
- Applicant
- NeuroPace, Inc.
- Applicant location
- Mountain View, CA
- Received
- Oct 17, 2022
- Decided
- Feb 10, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P100026
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for a revised the RNS System Implanting and Programming Program Qualifications Questionnaire as follows:1) Provided a list of current diagnostic technologies utilized to identify the seizure onset;2) Clarified that qualified neurosurgeon(s) are ABNS board-certified or board-eligible and tracking toward certification, with experience in epilepsy surgery procedures and placement of intracranial electrodes;3) Specified that an established referral relationship is needed to ensure access to neuropsychological testing and mental health services; and4) Neurologist(s) who is American Board of Psychiatry and Neurology (ABPN) board- certified and is fellowship trained in epilepsy or in clinical neurophysiology, or has experience in the treatment of epilepsy, including selection of antiepileptic medications, interpretation of scalp and intracranial EEG, video EEG monitoring, and selection of patients for epilepsy surgery or neuromodulation devices.2. Revised the RNS System Programming Physician Qualifications Questionnaire as follows:1) At least one American Board of Psychiatry and Neurology (ABPN) board-certified neurologist with expertise in epilepsy and in the interpretation of EEG;2) Established referral relationship with Epilepsy Program qualified to implant and program the RNS System;3) Local access to urgent or emergent neurosurgical care; and4) Capability to provide instructions to patient and family members in RNS System use.
Source documents
Other decisions for NeuroPace, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.